Mental Health

Researchers evaluated the lesser-known impact of telehealth treatments, including brief cognitive behavioral therapy (BCBT), to address the needs of individuals at risk of or recovering from suicidal ideation.

A recent retrospective, cross-sectional study found that detecting self-injurious thoughts and behaviors in youth requires improvement to ensure equitable identification of at-risk patients.

There are a few unmet needs in schizophrenia that can make a big difference in the prognosis and quality of life of patients.

While some adversities, like peer aggression, lead to worsening mental health, others, such as community threat, may result in adaptive suppression of symptoms.

In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.

Financial toxicity and patient and staff wellness were well explored at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference, serving as the focal point of multiple posters and presentations.

The Center on Health Equity & Access is dedicated to reducing health care disparities by exploring innovative solutions, policies, and research that advance health equity for diverse populations.

The extent to which certified community behavioral health clinic expansion reaches different parts of the country remained unclear until this study, which measured the proportion of US counties and populations within the service areas.

This interview accompanies the final podcast in our National Recovery Month series with Lyndra Bills, MD, senior medical director, and Shari Hutchison, MS, director of program evaluation and outcomes, both with Community Care Behavioral Health Organization, part of the UPMC Insurance Services Division.

Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of schizophrenia in adults.

This interview accompanies the fourth podcast in our National Recovery Month series with Amy Herschell, PhD, associate vice president, Program Implementation and Evaluation, Community Care Behavioral Health Organization, part of the UPMC Insurance Services Division, and Jessica Meyers, MSEd, senior advisor for implementation, UPMC Center for High-Value Health Care.

This interview accompanies the third podcast in our National Recovery Month series with Kim MacDonald-Wilson, ScD, CPRP, senior program director, Recovery and Wellness Transformation, and Tracy Carney, CPS, CPRP, senior recovery and resiliency specialist, Community Care Behavioral Health Organization.

Rachel Dalthorp, MD, discusses how zuranolone (Zurzuvae) can improve postpartum depression when compared with previous treatment approaches.

Results show that cognitive decline, combined with factors like smoking, obesity, and chronic health conditions, sharply increased the likelihood of premature death among patients with schizophrenia.

This interview accompanies the second podcast in our National Recovery Month series with Mandy Faubel, PhD, LCSW, UPMC Western Behavioral Health at Safe Harbor, and Rebekah Sedlock, DSW, LCSW, UPMC Insurance Services Division with Community Care.

Ali Khawar, Employee Benefits Security Administration, US Department of Labor, believes the final rule will be a benefit to employers and health plans that are trying to do the right thing and offer robust mental health benefits or substance use benefits.

While psychedelics like LSD and psilocybin are generally well tolerated in clinical and research settings, study authors suspect inconsistent reporting of adverse events.

This interview accompanies the first podcast in our National Recovery Month series with Michael Lynch, MD, attending emergency physician and medical toxicologist at the University of Pittsburgh Medical Center.

Brooke Kempf, PMHNP, from Indiana University Indianapolis, discusses the importance of timely outpatient care and how innovative approaches like long-acting injectables (LAIs) are helping to bridge the gap in treatment for schizophrenia.

Learn more about the negotiated Medicare drug prices and what the FDA's rejection of therapeutic MDMA means for mental health care through expert reactions. Other highlights include pharmacy-based HIV care, gaps in care for gastrointestinal stromal tumors, and the obesity epidemic.

The growing utilization of long-acting injectable (LAI) medications for treating patients with schizophrenia indicates a positive trend in mental health practice, according to Brooke Kempf, PMHNP, Indiana University Indianapolis.

The FDA's decision to reject midomafetamine (MDMA) capsules in combination with assisted psychotherapy (MDMA-AT) for adults with PTSD reignited the controversial conversation around investigative psychedelic therapy.

Along with the company reorganization, Lykos announced it will be reducing its workforce by approximately 75%, with the remaining team focused on continuing efforts in clinical development, medical affairs, and engagement with the FDA.

Today, the FDA issued a complete response letter (CRL) for midomafetamine capsules (MDMA) in combination with assisted therapy (MDMA-AT) for adults living with posttraumatic stress disorder (PTSD).

Over 60 bipartisan members of Congress wrote a letter to President Joe Biden stating the urgent need to address the suicide epidemic among veterans, advocating for innovative treatments like therapeutic MDMA.

The Center on Health Equity & Access reported on new research in youth mental health, with expert perspectives on HIV, liver cancer, and health outreach.

Researchers analyzed the availability of telehealth services at mental health treatment facilities across the US before and after the end of the COVID-19 public health emergency through a national secret shopper analysis.

Those in minority groups face barriers even after they’ve made the hard decision to seek mental health care. The Department of Labor aims to address systemic issues on a personal level.

Roughly 7% of US women of reproductive age have attempted self-induced abortions after the overturning of Roe v Wade in 2022; the FDA announced that the cost to file a drug using clinical data will increase to about $4.3 million in 2025; the suicide rate among US children aged between 8 to 12 years has steadily risen during the past 15 years.

Suicide has emerged as the leading cause of death among Asian American and Pacific Islander (AAPI) youths, a demographic that is rapidly growing in the United States.